Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)
Enrolling By Invitation
18-99 years
All
Phase
2
1 Location
Brief description of study
This is a randomized phase 2 open label study of sacituzumab govitecan +/-
pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative
breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer
and who have not received a prior PD-1/L1 inhibitor
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Breast Cancer
Updated on
01 Aug 2024.
Study ID: 850026
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
